Precision Biosciences Inc
DTIL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001357874
In the last 90 days, Precision Biosciences Inc insiders filed 3 open-market purchases and 1 sale; 96 institutions reported holding it in 13F filings for Q2 2026, worth $139.5M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 12, 2026
- $224.6M
- Insider buysLast 90 days, $29.5K in total
- 3
- Insider sellsLast 90 days, $27.5K in total
- 1
- 13F holdersQ2 2026, +18 vs. previous quarter
- 96
- 13F valueReported value at the end of Q2 2026
- $139.5M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $34.3M
- −50.1% year over year
- Net income, FY2025
- -$45.7M
- −738.0% year over year
- Free cash flow, FY2025
- -$65.9M
- No comparable prior period
- Revenue, Q3 FY2026
- $0
- −100.0% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $45.7M (133.4% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 2.10M
- Shares sold short
- Change
- −259.9K
- −11.0% vs. previous
- Days to cover
- 10.52
- At average daily volume
Superinvestors holding DTIL, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding DTIL at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Precision Biosciences Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 12, 2026 (view filing)4:11 PM ET | Nov 10 | 2 days | Scimeca DarioChief Legal Officer | SSale | −2.82K | $9.75 | −$27.5K | −4.7%56.8K after | 10b5-1 |
| Sep 30, 2026 (view filing)4:15 PM ET | Sep 28 | 2 days | Frankel StanleyDirector | PPurchase | +1.00K | $6.00 | +$6.00K | +2.5%41.5K after | |
| Sep 29, 2026 (view filing)7:00 AM ET | Sep 25 | 4 days | Brown MelindaDirector | PPurchase | +1.14K | $6.27 | +$7.12K | +2.6%45.5K after | |
| Sep 29, 2026 (view filing)7:00 AM ET | Sep 25 | 4 days | Germano Geno JDirector | PPurchase | +2.61K | $6.28 | +$16.4K | +5.8%47.5K after | |
| Feb 19, 2026 (view filing) | Feb 18 | 1 day | Amoroso MichaelPresident and CEO | SSale | −20.6K | $3.84 | −$78.9K | −7.8%243.4K after | 10b5-1 |
| Feb 19, 2026 (view filing) | Feb 18 | 1 day | Kelly John AlexanderChief Financial Officer | SSale | −8.15K | $3.84 | −$31.3K | −6.1%125.9K after | 10b5-1 |
| Feb 19, 2026 (view filing) | Feb 18 | 1 day | Scimeca DarioGeneral Counsel and Secretary | SSale | −4.92K | $3.84 | −$18.9K | −8.0%56.5K after | 10b5-1 |
| Feb 19, 2026 (view filing) | Feb 18 | 1 day | Smith J. JeffersonChief Research Officer | SSale | −4.92K | $3.84 | −$18.9K | −3.9%121.9K after | 10b5-1 |
| Jan 22, 2026 (view filing) | Jan 22 | Same day | Amoroso MichaelPresident and CEO | SSale | −34.8K | $4.17 | −$145.1K | −15.1%196.2K after | 10b5-1 |
| Jan 22, 2026 (view filing) | Jan 21 | 1 day | Scimeca DarioGeneral Counsel and Secretary | SSale | −8.85K | $4.03 | −$35.7K | −16.5%44.7K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 96 holdersThe largest institutional positions in Precision Biosciences Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Standard Life Aberdeen plc | 2,230,178 | $17.5M | 0.02% | 00.0% | Unchanged |
| Bleichroeder LP | 2,018,190 | $15.9M | 2.84% | +355,690+21.4% | Added |
| Octagon Capital Advisors LP | 1,350,000 | $10.6M | 0.97% | −886,732−39.6% | Reduced |
| Boothbay Fund Management, LLC | 1,346,004 | $10.6M | 0.20% | +279,954+26.3% | Added |
| BlackRock, Inc. | 1,172,873 | $9.22M | 0.00% | +973,112+487.1% | Added |
| Vanguard Capital Management LLC | 1,116,241 | $8.77M | 0.00% | +205,501+22.6% | Added |
| Lynx1 Capital Management LP | 950,466 | $7.47M | 0.86% | −34,647−3.5% | Reduced |
| Driehaus Capital Management LLC | 946,707 | $7.44M | 0.04% | −48,664−4.9% | Reduced |
| Empery Asset Management, LP | 776,093 | $6.10M | 7.05% | −1,192,786−60.6% | Reduced |
| Affinity Asset Advisors, LLC | 646,576 | $5.08M | 0.25% | +48,630+8.1% | Added |
Holders of 5% or more of DTIL
See all 6 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Precision Biosciences Inc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Readout Capital, LP | 13G/A | 9.40%1.12M shares | +0.50 ppfrom 8.90% | Mar 26, 20252 filings | Aug 14, 2025 | SEC |
| Standard Life Aberdeen plc | 13G | 8.88%2.14M shares | New | Jan 27, 20261 filing | Jan 27, 2026 | SEC |
| Bleichroeder LP | 13G/A | 8.21%1.90M shares | −1.48 ppfrom 9.69% | Aug 14, 20252 filings | Feb 13, 2026 | SEC |
| Octagon Capital Advisors LP | 13G/A | 5.73%1.65M shares | −4.26 ppfrom 9.99% | Feb 10, 20262 filings | Nov 3, 2026 | SEC |
| Lynx1 Capital Management LP | 13G | 5.40%1.39M shares | +1.30 ppfrom 4.10% | Feb 14, 20254 filings | Jul 20, 2026 | SEC |